Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

550 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery.
Bundred N, Gardovskis J, Jaskiewicz J, Eglitis J, Paramonov V, McCormack P, Swaisland H, Cavallin M, Parry T, Carmichael J, Dixon JM. Bundred N, et al. Among authors: dixon jm. Invest New Drugs. 2013 Aug;31(4):949-58. doi: 10.1007/s10637-012-9922-7. Epub 2013 Jan 13. Invest New Drugs. 2013. PMID: 23315029 Clinical Trial.
Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.
Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ. Mansel RE, et al. Among authors: dixon jm. J Natl Cancer Inst. 2006 May 3;98(9):599-609. doi: 10.1093/jnci/djj158. J Natl Cancer Inst. 2006. PMID: 16670385 Clinical Trial.
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Bundred NJ, Cramer A, Morris J, Renshaw L, Cheung KL, Flint P, Johnson R, Young O, Landberg G, Grassby S, Turner L, Baildam A, Barr L, Dixon JM. Bundred NJ, et al. Among authors: dixon jm. Clin Cancer Res. 2010 Mar 1;16(5):1605-12. doi: 10.1158/1078-0432.CCR-09-1623. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179229 Clinical Trial.
Carcinoma in situ.
Bundred N, Dixon JM. Bundred N, et al. Among authors: dixon jm. BMJ. 2013 Dec 23;347:f3289. doi: 10.1136/bmj.f3289. BMJ. 2013. PMID: 24365752 Review. No abstract available.
Opportunities and priorities for breast surgical research.
Cutress RI, McIntosh SA, Potter S, Goyal A, Kirwan CC, Harvey J, Francis A, Carmichael AR, Vidya R, Vaidya JS, Fairbrother P, Benson JR, Reed MWR; Association of Breast Surgery Surgical Gap Analysis Working Group. Cutress RI, et al. Lancet Oncol. 2018 Oct;19(10):e521-e533. doi: 10.1016/S1470-2045(18)30511-4. Epub 2018 Oct 1. Lancet Oncol. 2018. PMID: 30303126 Review.
MRI breast screening in high-risk women: cancer detection and survival analysis.
Evans DG, Kesavan N, Lim Y, Gadde S, Hurley E, Massat NJ, Maxwell AJ, Ingham S, Eeles R, Leach MO; MARIBS Group; Howell A, Duffy SW. Evans DG, et al. Breast Cancer Res Treat. 2014 Jun;145(3):663-72. doi: 10.1007/s10549-014-2931-9. Epub 2014 Apr 1. Breast Cancer Res Treat. 2014. PMID: 24687378
Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research.
Moossdorff M, van Roozendaal LM, Strobbe LJ, Aebi S, Cameron DA, Dixon JM, Giuliano AE, Haffty BG, Hickey BE, Hudis CA, Klimberg VS, Koczwara B, Kühn T, Lippman ME, Lucci A, Piccart M, Smith BD, Tjan-Heijnen VC, van de Velde CJ, Van Zee KJ, Vermorken JB, Viale G, Voogd AC, Wapnir IL, White JR, Smidt ML. Moossdorff M, et al. Among authors: dixon jm. J Natl Cancer Inst. 2014 Nov 7;106(12):dju288. doi: 10.1093/jnci/dju288. Print 2014 Dec. J Natl Cancer Inst. 2014. PMID: 25381395 Free PMC article.
550 results